A phase 2 study evaluated SHR-1701, a TGF-β inhibitor, combined with XELOX and bevacizumab as first-line treatment for unresectable metastatic colorectal cancer (mCRC).
Combination therapy with SHR-1701 and famitinib demonstrates encouraging objective response rates in biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC) patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.